Linked Life Data

12409423

Source:http://linkedlifedata.com/resource/pubmed/id/12409423

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2002-10-31
pubmed:abstractText
The revised interpretive criteria for Streptococcus pneumoniae recently published in the NCCLS M100-S12 informational supplement provide two sets of breakpoints for some cephalosporins: one set for meningeal infection isolates and a new set for nonmeningeal infection isolates. The net effect of these changes was to increase the reported rates of susceptibility of S. pneumoniae to the more active parenteral cephalosporins, such as cefepime, cefotaxime, and ceftriaxone, by 9.1 to 13.0%, bringing their in vitro rates much closer to those of amoxicillin (modified in an earlier NCCLS publication). These revised breakpoints will assist the rational prescribing of antimicrobial agents for the treatment of pneumococcal infections for specific types of infection and establish a greater correlation with clinical outcomes.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0095-1137
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4332-3
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY antimicrobial surveillance program (1997 to 2001).
pubmed:affiliation
The JONES Group/JMI Laboratories, North Liberty, Iowa 52317, USA. ronald.jones@jmilabs.com
pubmed:publicationType
Journal Article, Evaluation Studies